U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C37H48N6O5S2
Molecular Weight 720.944
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of RITONAVIR

SMILES

CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC2=CC=CC=C2)NC(=O)OCC3=CN=CS3)CC4=CC=CC=C4

InChI

InChIKey=NCDNCNXCDXHOMX-XGKFQTDJSA-N
InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1

HIDE SMILES / InChI
Molecular Formula C37H48N6O5S2
Molecular Weight 720.944
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:29:49 UTC 2023
Edited
by admin
on Fri Dec 15 15:29:49 UTC 2023
Record UNII
O3J8G9O825
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
RITONAVIR
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   VANDF   WHO-DD   WHO-IP  
INN   USAN  
Official Name English
NORVIR
Brand Name English
RITONAVIR [VANDF]
Common Name English
RITONAVIR [MI]
Common Name English
VIRITON
Brand Name English
EMPETUS
Brand Name English
PAXLOVID COMPONENT RITONAVIR
Brand Name English
ritonavir [INN]
Common Name English
ABBOTT-84538
Code English
VIEKIRAX COMPONENT RITONAVIR
Brand Name English
RITOVIR
Brand Name English
KALETRA COMPONENT RITONAVIR
Common Name English
RITONAVIR [HSDB]
Common Name English
RITONAVIR [USP-RS]
Common Name English
NSC-693184
Code English
ABT-538
Code English
RITONAVIR COMPONENT OF PAXLOVID
Brand Name English
RITONAVIR COMPONENT OF VIEKIRAX
Brand Name English
RTV
Common Name English
RITONAVIR [EMA EPAR]
Common Name English
RITONAVIR [JAN]
Common Name English
Ritonavir [WHO-DD]
Common Name English
RITONAVIR COMPONENT OF KALETRA
Common Name English
RITONAVIR [ORANGE BOOK]
Common Name English
RITONAVIRUM [WHO-IP LATIN]
Common Name English
A-84538
Code English
RITOMUNE
Brand Name English
RITONAVIR RELATED COMPOUNDS MIXTURE
USP-RS  
Common Name English
2,7,10,12-TETRAAZATRIDECANOIC ACID, 4-HYDROXY-12-METHYL-9-(1-METHYLETHYL)-13-(2-(1-METHYLETHYL)-4-THIAZOLYL)-8,11-DIOXO-3,6-BIS(PHENYLMETHYL)-, 5-THIAZOLYLMETHYL ESTER, (3S,4S,6S,9S)-
Systematic Name English
RITONAVIR [MART.]
Common Name English
2,4,7,12-TETRAAZATRIDECAN-13-OIC ACID, 10-HYDROXY-2-METHYL-5-(1-METHYLETHYL)-1-(2-(1-METHYLETHYL)-4-THIAZOLYL)-3,6-DIOXO-8,11-BIS(PHENYLMETHYL)-5-THIAZOLYLMETHYL ESTER (5S-(5R*,8R*,10R*,11R*))-
Common Name English
RITONAVIR [USP IMPURITY]
Common Name English
RITONAVIR [USP MONOGRAPH]
Common Name English
RITONAVIR RELATED COMPOUNDS MIXTURE [USP-RS]
Common Name English
RITONAVIR [WHO-IP]
Common Name English
VIEKIRAX
Brand Name English
5-Thiazolylmethyl [(αS)-α-[(1S,3S)-1-hydroxy-3-[(2S)-2-[3-[(2-isopropyl-4-thiazolyl)methyl]-3-methylureido]-3-methylbutyramido]-4-phenylbutyl]phenethyl]carbamate
Common Name English
RITONAVIR [USAN]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548747
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AR10
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AE03
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-VATC QJ05AE03
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-VATC QJ05AR10
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AP52
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
EMA ASSESSMENT REPORTS LOPINAVIR (AUHTORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AX66
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
FDA ORPHAN DRUG 549816
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
NCI_THESAURUS C97366
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
FDA ORPHAN DRUG 509215
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
EMA ASSESSMENT REPORTS KALETRA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.3 (LPV/R)
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AR23
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AP53
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
NDF-RT N0000191001
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
NDF-RT N0000175889
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
FDA ORPHAN DRUG 484715
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
NDF-RT N0000000246
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
EMA ASSESSMENT REPORTS VIEKIRAX (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
WHO-ATC J05AX67
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
EMA ASSESSMENT REPORTS NORVIR (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
Code System Code Type Description
WHO INTERNATIONAL PHARMACOPEIA
RITONAVIR
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Description: A white or almost white powder. Solubility: Practically insoluble in water, freely soluble in methanol R, sparingly soluble in acetone R and very slightly soluble in acetonitrile R. Category: Antiretroviral (Protease Inhibitor). Storage: Ritonavir should be kept in a well-closed container, protected from light. Additional information: Ritonavir may exhibit polymorphism. Requirements: Ritonavir contains not less than 98.5 % and not more than 101.0 % of C37H48N6O5S2, calculated with reference to the dried substance.
FDA UNII
O3J8G9O825
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
ChEMBL
CHEMBL163
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
RS_ITEM_NUM
1604803
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
INN
7449
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
EVMPD
SUB10342MIG
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
WIKIPEDIA
RITONAVIR
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
RXCUI
85762
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY RxNorm
NDF-RT
N0000182137
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 2D6 Inhibitors [MoA]
NDF-RT
N0000182141
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 3A4 Inhibitors [MoA]
NDF-RT
N0000187064
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 2B6 Inducers [MoA]
DRUG BANK
DB00503
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
MESH
D019438
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
LACTMED
Ritonavir
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NDF-RT
N0000185607
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 2C19 Inducers [MoA]
DRUG CENTRAL
2391
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NDF-RT
N0000191266
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 1A2 Inducers [MoA]
SMS_ID
100000089167
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NDF-RT
N0000190113
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Breast Cancer Resistance Protein Inhibitors [MoA]
CHEBI
45409
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NDF-RT
N0000185507
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 2C9 Inducers [MoA]
EPA CompTox
DTXSID1048627
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NDF-RT
N0000190117
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY UDP Glucuronosyltransferases Inducers [MoA]
NDF-RT
N0000190118
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 3A Inducers [MoA]
NSC
693184
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
DAILYMED
O3J8G9O825
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
MERCK INDEX
m9636
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Merck Index
NDF-RT
N0000190114
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
PUBCHEM
392622
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
HSDB
7160
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
IUPHAR
8804
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NCI_THESAURUS
C1609
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
CAS
155213-67-5
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
NDF-RT
N0000185503
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
USAN
GG-103
Created by admin on Fri Dec 15 15:29:49 UTC 2023 , Edited by admin on Fri Dec 15 15:29:49 UTC 2023
PRIMARY
Related Record Type Details
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INHIBITOR
SOLUTE CARRIER FAMILY 21 MEMBER 3
TRANSPORTER -> INHIBITOR
OATP-8
TRANSPORTER -> INHIBITOR
Structure of RITONAVIR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 2D6
METABOLIC ENZYME -> INHIBITOR
POTENT
CYTOCHROME P450 3A4
METABOLIC ENZYME -> INHIBITOR
POTENT
CYTOCHROME P450 2C9
METABOLIC ENZYME -> INHIBITOR
POTENT
OATP1B1
TRANSPORTER -> INHIBITOR
CYTOCHROME P450 2C19
METABOLIC ENZYME -> INDUCER
OATP-B
TRANSPORTER -> INHIBITOR
OCT-1
TRANSPORTER -> INHIBITOR
Structure of RITONAVIR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1
TARGET ORGANISM->INHIBITOR
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE
TARGET -> INHIBITOR
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> SUBSTRATE
MULTIDRUG RESISTANCE PROTEIN 1
TRANSPORTER -> INDUCER
Related Record Type Details
Structure of THIAZOL-5-YLMETHYL N-((1S,2S,4S)-1-BENZYL-2-HYDROXY-4-(((2S)-2-((HYDROXYMETHYL-((2-ISOPROPYLTHIAZOL-4-YL)METHYL)CARBAMOYL)AMINO)-3-METHYL-BUTANOYL)AMINO)-5-PHENYL-PENTYL)CARBAMATE
METABOLITE -> PARENT
MINOR
Structure of THIAZOL-5-YLMETHYL N-((1S,2S,4S)-1-BENZYL-2-HYDROXY-4-(((2S)-2-((HYDROXY-((2-ISOPROPYLTHIAZOL-4-YL)METHYL)CARBAMOYL)AMINO)-3-METHYL-BUTANOYL)AMINO)-5-PHENYL-PENTYL)CARBAMATE
METABOLITE INACTIVE -> PARENT
MINOR
FECAL
Structure of HYDROXYRITONAVIR
METABOLITE ACTIVE -> PARENT
37.3% in feces 30.4% in urine
MAJOR
FECAL; URINE
Structure of HYDROXYRITONAVIR
METABOLITE ACTIVE -> PARENT
MAJOR
Structure of THIAZOL-5-YLMETHYL N-((1S,2S,4S)-1-BENZYL-2-HYDROXY-4-(((2S)-3-METHYL-2-(METHYLCARBAMOYLAMINO)BUTANOYL)AMINO)-5-PHENYL-PENTYL)CARBAMATE
METABOLITE ACTIVE -> PARENT
MAJOR
FECAL
Related Record Type Details
Structure of THIAZOL-5-YLMETHYL ((1S,2S,4S)-1-BENZYL-4-(((1,1-DIMETHYLETHOXY)CARBONYL)AMINO)-2-HYDROXY-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of UREIDOVALINE ISOBUTYL ESTER
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of THIAZOL-5-YLMETHYL ((1S,2S,4S)-1-BENZYL-4-(((1,1-DIMETHYLETHOXY)CARBONYL)AMINO)-2-HYDROXY-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol- 0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of UREIDOVALINE ISOBUTYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESTHIAZOLYLMETHYL RITONAVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of UREIDOVALINE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of HYDROXYRITONAVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of RITONAVIR 4-HYDROXY ISOMER
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of A-81272
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of RITONAVIR HYDROPEROXIDE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of RITONAVIR HYDROPEROXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of THIAZOL-5-YLMETHYL ((1S,2S,4S)-4-(ACETYLAMINO)-1-BENZYL-2-HYDROXY-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DES(ISOPROPYLTHIAZOLYL) HYDANTOIN-OXAZOLIDINONE RITONAVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 2-DESISOPROPYL-2-ETHYL RITONAVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of UREIDOVALINE
IMPURITY -> PARENT
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DES(ISOPROPYLTHIAZOLYL) HYDANTOIN-OXAZOLIDINONE RITONAVIR
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of HYDROXYRITONAVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of RITONAVIR 4-HYDROXY ISOMER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of THIAZOL-5-YLMETHYL ((1S,2S,4S)-1-BENZYL-4-(((2S)-1-BENZYL-2-HYDROXY-4-((4S)-4-(1-METHYLETHYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL)-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DES((2-ISOPROPYLTHIAZOL-4-YL)METHYL-METHYL-CARBAMOYL)RITONAVIR
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of THIAZOL-5-YLMETHYL ((1S,2S,4S)-1-BENZYL-4-(((2S)-1-BENZYL-2-HYDROXY-4-((4S)-4-(1-METHYLETHYL)-2,5-DIOXOIMIDAZOLIDIN-1-YL)-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of THIAZOL-5-YLMETHYL ((1S,2S,4S)-4-(ACETYLAMINO)-1-BENZYL-2-HYDROXY-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of THIAZOL-5-YLMETHYL (1S,2S,4S)-1-BENZYL-2-HYDROXY-4-(((2-METHYLPROPOXY)CARBONYL)AMINO)-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
Mixture of BOC-aminoalcohol and isobutoxycarbonyl aminoalcohol-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 2-DESISOPROPYL-2-ETHYL RITONAVIR
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of DES((2-ISOPROPYLTHIAZOL-4-YL)METHYL-METHYL-CARBAMOYL)RITONAVIR
IMPURITY -> PARENT
Mixture of ureidovaline and N-deacylvaline ritonavir-0.1
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of A-81272
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of THIAZOL-5-YLMETHYL (1S,2S,4S)-1-BENZYL-2-HYDROXY-4-(((2-METHYLPROPOXY)CARBONYL)AMINO)-5-PHENYLPENTYL)CARBAMATE
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of DESTHIAZOLYLMETHYL RITONAVIR
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of RITONAVIR
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966